Current Vascular Pharmacology

Dimitri P. Mikhailidis  
Academic Head, Deptartment of Clinical Biochemistry
Royal Free Hospital Campus
University College London Medical School
University College London (UCL)
Pond Street
London, NW3 2QG


Controversies on HDL: Should it be a Target Biomarker in Patients with Lipid Disorders?

Author(s): Stephen J. Nicholls, Jordan Andrews and MyNgan Duong

Affiliation: South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA, 5001, Australia.

Keywords: Atherosclerosis, high-density lipoproteins, lipids, risk factors.


Low-density lipoprotein (LDL) cholesterol lowering with statins have had a profound impact on cardiovascular (CV) event rates and accordingly have become an integral component of strategies designed to reduce CV risk. The finding of a residual clinical risk, despite LDL cholesterol lowering, supports the need to develop additional therapeutic strategies for CV prevention. Numerous lines of evidence suggest that targeting the protective properties of high-density lipoproteins (HDL) may be beneficial. Disappointing results from recent reports of HDL genetics and raising agents and clinical events has fueled considerable debate as to whether attempts to target HDL will be of clinical benefit or futility. This review will reflect on challenges faced in developing new effective HDL targeted therapies.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [649 - 652]
Pages: 4
DOI: 10.2174/1570161112999140411131155